ESTRO 2025 - Abstract Book

S1404

Clinical - Lung

ESTRO 2025

Material/Methods: Between August-2017 and January-2024, 125 consecutive NSCLC patients treated with hypofractionated radiotherapy were prospectively registered. Most frequent radiotherapy schedule: 55Gy in 20 fractions (85.5% of the patients), with or without concurrent or previous chemotherapy. Results: 110 patients were analysed: 9 stage II, 86 stage III, and 15 stage IV NSCLC. 51 received concurrent radiochemotherapy (Conc-RChT), 42 sequential chemotherapy and radiotherapy (Seq-RChT), and 17 only radiotherapy (RT). Median overall survival was 20.7 months for Conc-RChT, 17.2 months for Seq-RChT, and 6.1 for exclusive RT (p=0.05). There were statistically significant differences in overall survival between patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-1: 15.2 months; and with ECOG-PS 2-3: 5.7 months (p = 0.036). Toxicity: acute esophagitis 30% grade 1, 16.4% grade 2, 2.7% grade 3. Acute pneumonitis: 12.7% grade 1, 9.1% grade 2. Late grade 1 pneumonitis: 4.5%.